ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, advancing, and bringing to market treatments addressing critical gaps in cancer patient care. The company specifically focuses on developing and commercializing targeted oncology therapies for conditions like non-small-cell lung cancer (NSCLC) and various solid tumor indications. Among its pipeline candidates are Furmonertinib, an epidermal growth factor receptor (EGFR) mutant-selective tyrosine kinase inhibitor currently undergoing a Phase 3 clinical trial for NSCLC treatment, and ARR-002. ArriVent maintains strategic alliances, including one with Aarvik Therapeutics Inc. Established in 2021, its operations are headquartered in Newtown Square, Pennsylvania.
